Hydroxychloroquine (HCQ) in Oncology — India Price, Cancer Trials & Access Guide 2026

Hydroxychloroquine — a 70-year-old antimalarial drug costing ₹5/day in India — has been tested in over 50 cancer clinical trials. The results range from extraordinary (85% response rates in melanoma, 100% cancer-free survival in breast cancer prevention) to outright failure (0% response in lung and pancreatic cancers). No other repurposed drug in oncology provokes this much contradiction.

Here is what the evidence actually shows as of 2026, what it costs, and what Indian patients need to know.

How Hydroxychloroquine Works Against Cancer

HCQ was originally thought to work through a single mechanism: autophagy inhibition. Cancer cells use autophagy (cellular self-eating) to survive chemotherapy stress. HCQ blocks this survival pathway by alkalinizing lysosomes, preventing the final digestion step.

But 2024–2025 research has revealed at least three additional anti-cancer mechanisms:

1. MHC-I Restoration (AACR 2025)

Tumors hide from the immune system by degrading MHC-I molecules on their surface. HCQ reverses this — significantly elevating MHC-I levels on melanoma, lung, ovarian, and brain cancer cells (p < 0.01). The effect persists for 72 hours after stopping HCQ. This pre-treatment enhanced T-cell killing efficiency against NY-ESO-1 positive tumors.

2. Myeloperoxidase Inhibition (Journal of Inflammation, 2025)

HCQ directly binds myeloperoxidase (Kd = 9.74 mM), blocking substrate access to the heme group. This reduces metastatic tumor burden through a neutrophil extracellular trap-independent pathway. Validated in metastatic pancreatic cancer patients receiving neoadjuvant chemotherapy.

3. PAR-4 Tumor Suppressor Induction

Phase I clinical trial data showed tumor cell death occurred ONLY in patients whose circulating PAR-4 protein levels increased. This suggests the actual anti-cancer effect may be driven by tumor suppressor induction — not autophagy inhibition at all.

The Fundamental Problem

At 600mg/day in glioblastoma, autophagy inhibition was NOT consistently achieved. At 1200mg/day (the maximum tolerated), results remain inconsistent. If HCQ cannot reliably inhibit autophagy at tolerable doses, the entire original rationale is questionable — making these alternative mechanisms critically important.

Clinical Trial Results by Cancer Type

Melanoma: The Strongest Signal

BAMM Trial (Phase I/II, 2022)

• Combination: Dabrafenib + trametinib + HCQ 1200mg/day
• 34 patients with BRAF V600-mutant melanoma
• Overall response rate: 85%
• Complete response: 41%
• Median PFS: 11.2 months
• No dose-limiting toxicities, no ocular toxicity
• For comparison: DREAMseq study (similar population) achieved only 43% response

BAMM2/EA6191 (Ongoing, Randomized Phase II)

• The closest thing to a definitive test of HCQ in cancer
• Randomized: dabrafenib + trametinib + HCQ vs. placebo
• Stage IIIC/IV BRAF V600E/K melanoma, elevated LDH, post-immunotherapy
• PI: Ravi Amaravadi, UPenn; ECOG-ACRIN led
• Currently recruiting

Breast Cancer: Prevention of Recurrence

CLEVER Trial (Nature Medicine, 2025)

• 53 patients randomized: HCQ alone, everolimus alone, HCQ+everolimus
• Target: Eliminating dormant tumor cells (DTCs) in bone marrow after surgery
• 3-year recurrence-free survival: HCQ+everolimus = 100%
• DTC reduction: HCQ 80%, everolimus 78%, combination 87%
• At 77-month follow-up: only 2/51 (6%) had any recurrence
• No grade 4/5 toxicities

Phase I: HCQ + Palbociclib + Letrozole (2025)

• 14 patients, ER+/HER2- metastatic breast cancer
• Best responses: 2 partial responses, 11 stable disease
• Tumor reductions of 11–30%
• 79% had only Grade 1–2 adverse events

Pancreatic Cancer: Mostly Disappointing

Trial	N	Response	Median PFS	Median OS
Preop Gem/NabPac + HCQ (Phase II)	98	56% path response vs 10% control (p=0.00016)	—	36 vs 32 mo (NS)
Met Gem/NabPac + HCQ (JAMA Oncology)	112	38% vs 21% (significant)	—	12-mo OS: 41% vs 49% (HCQ WORSE)
Binimetinib + HCQ HOPE (2026)	34	6.5%	1.9 mo	5.3 mo
LY3214996 + HCQ (2025)	39	5% DCR	1.3 mo	2.4 mo (combo WORSE)
Trametinib/HCQ Germany (2024)	19	0% response	52 days	68 days

The pattern is striking: HCQ improves tumor shrinkage in pancreatic cancer but does NOT improve — and may worsen — overall survival.

Other Cancers

Cancer	Trial	Key Result
Renal cell carcinoma	Everolimus + HCQ (Phase I/II)	67% disease control, median PFS 6.3 mo (vs 4.0 historical)
Colorectal	FOLFOX/Bev + HCQ (Phase II)	52% response, 1-yr OS 74%
Colorectal	Vorinostat/HCQ vs regorafenib	HCQ arm INFERIOR (PFS 1.9 vs 4.35 mo)
NSCLC (KRAS)	Binimetinib + HCQ (Phase II)	0% response (0/9 patients)
Glioblastoma	HCQ + RT + temozolomide	Autophagy not inhibited at tolerable doses
Prostate	HCQ monotherapy (PAR-4 trial)	Presented ASCO 2025, data pending

The Critical Contradictions

1. Shrinks Tumors But Doesn’t Extend Life

In preoperative pancreatic cancer, HCQ produced a dramatic 56% pathologic response rate vs 10% without (p = 0.00016). Yet median overall survival was statistically identical (36 vs 32 months). This pattern repeats across multiple cancer types.

2. Helps Immune Recognition But Harms Immunotherapy

HCQ upregulates MHC-I on cancer cells (AACR 2025), which should make tumors MORE visible to T-cells. But in melanoma mice, HCQ partially reversed anti-PD-1 immunotherapy benefit by suppressing CD8+ tumor-infiltrating lymphocytes (PLOS ONE 2021). The net effect on combined immunotherapy is unknown — the LIMIT trial (NCT04464759) is testing this.

3. Works for Prevention, Not Treatment

Lupus patients on standard-dose HCQ (400mg/day) have 30% reduced cancer risk (RR 0.70, meta-analysis of 9 studies). But 3x higher doses in active cancer trials consistently fail to improve survival. Chronic low-dose exposure may work through entirely different biology than acute high-dose treatment.

Hydroxychloroquine Price: India vs US vs UK

Parameter	India	US (Generic)	US (Brand Plaquenil)	UK
200mg tablet (unit cost)	₹9–15 ($0.11–$0.18)	$0.30–$0.50 (with coupons)	$3.00+	£0.15–£0.30
Monthly cost (400mg/day — autoimmune)	₹540–900 ($7)	$15–40	$360+	£9–18
Monthly cost (800mg/day — oncology)	₹1,080–1,800 ($13–22)	$45–80	$720+	£18–36
Monthly cost (1200mg/day — max trial dose)	₹1,620–2,700 ($20–33)	$70–120	$1,080+	£27–54

India Manufacturing Context

• Ipca Laboratories is the world’s largest HCQ manufacturer
• India supplies 70%+ of global HCQ demand
• India tripled production capacity during COVID-19 (capacity retained)
• At least 8 generic brands available on 1mg.com and other pharmacies
• No supply constraints exist in 2026

Why HCQ is Uniquely Positioned for India

At $13–33/month for cancer-dose HCQ, this is one of the cheapest potential cancer drugs in existence. For comparison:

• Pembrolizumab (Keytruda): $8,000–$15,000/month in US, $1,500–$3,000 in India
• Dabrafenib + trametinib: $15,000/month in US, $1,000–$2,500 in India
• HCQ: $13–33/month in India

The ReDO (Repurposing Drugs in Oncology) project specifically highlights HCQ’s relevance for developing countries where expensive new cancer drugs are inaccessible.

Dosing: Oncology vs Autoimmune

Indication	Dose	Duration	Eye Monitoring
Lupus/RA	200–400 mg/day	Years to lifetime	Annual after 5 years
Melanoma (BAMM trial)	1200 mg/day (600 BID)	Until progression	Monthly OCT recommended
Breast cancer (CLEVER)	Not disclosed	12 months	Per protocol
Pancreatic (most trials)	1200 mg/day (600 BID)	Until progression	Quarterly minimum
NSCLC (erlotinib combo)	1000 mg/day	Until progression	Monthly OCT recommended
Ophthalmology safe limit	≤5 mg/kg/day (350mg for 70kg)	—	—

Critical safety note: Oncology doses exceed the ophthalmology-safe threshold by 2–3x. At these doses, retinal damage has been documented in 11–17 months (vs. years at autoimmune doses).

Safety at Oncology Doses

Retinal Toxicity (Irreversible)

• At 1000mg/day: 2/7 patients (29%) developed subclinical retinal damage within 11–17 months
• Standard screening MISSED it — only detected by high-resolution OCT and multifocal electroretinography
• Concurrent tamoxifen or chemotherapy (docetaxel, cyclophosphamide) accelerates damage
• Retinal damage does NOT reverse after stopping HCQ
• At standard doses (400mg/day): 7.5% prevalence after 5+ years, 20% after 20 years

Cardiac Toxicity (HOPE Trial, 2026)

• Troponin T elevation: 26% of patients
• QT prolongation: 21% of patients
• Ejection fraction decrease: 9%
• One dose-limiting toxicity was Grade 3 QT prolongation attributed to HCQ

Common Side Effects at Cancer Doses

• Rash: 76% (with binimetinib combination)
• Diarrhea: 26–47%
• Nausea: 12–30%
• Insomnia: 26% (with FOLFOX)
• Anxiety: 20%
• Visual disturbances: 11%

Next-Generation Autophagy Inhibitors (Replacing HCQ)

HCQ’s limitations — low potency, inconsistent tumor autophagy inhibition, retinal toxicity — have driven development of purpose-built cancer autophagy inhibitors:

Drug	Mechanism	Developer	Stage	Key Advantage
DCC-3116 (Inlexisertib)	ULK1/2 kinase inhibitor	Deciphera Pharmaceuticals	Phase 1/2	Blocks autophagy initiation (upstream), not just lysosomes
GNS561 (Ezurpimtrostat)	PPT1 inhibitor	Genoscience Pharma	Phase 1b complete	200mg BID RP2D; entering Phase 2 for HCC
DC661/DQ661	PPT1 inhibitor	Amaravadi Lab (UPenn)	Preclinical	Works in acidic tumor microenvironment (HCQ does not)
Lys05	Lysosomal inhibitor	Academic	Preclinical	~10x more potent than HCQ
ROC-325	Lysosomal autophagy inhibitor	Academic	Preclinical	Developed to “move beyond HCQ”
EAD1	Chloroquine analog	Academic	Preclinical	~8x more potent than HCQ

DCC-3116 represents the most fundamental shift: rather than blocking the lysosome (downstream, like HCQ), it blocks autophagy initiation at ULK1/2 (upstream). Currently being tested with sotorasib (KRAS G12C inhibitor), trametinib, and ripretinib.

Who Should Consider HCQ for Cancer?

Based on current trial data, the strongest evidence supports:

1. BRAF V600-mutant melanoma — patients who have progressed on immunotherapy, considering dabrafenib + trametinib backbone (ask about BAMM2 trial enrollment)
2. Early-stage ER+ breast cancer — post-surgery patients with detectable disseminated tumor cells (ask about CLEVER-like protocols or PALAVY trial)
3. Borderline-resectable pancreatic cancer — neoadjuvant setting with gemcitabine/nab-paclitaxel (pathologic response benefit, survival benefit unproven)

Who Should NOT Use HCQ for Cancer

• Patients currently on anti-PD-1/PD-L1 immunotherapy (potential interference)
• Patients on tamoxifen (accelerated retinal toxicity)
• Patients with pre-existing cardiac QT prolongation
• Patients with renal impairment (altered HCQ clearance)
• Any patient without monthly ophthalmologic monitoring at doses >400mg/day

Medical Tourism Considerations

Why Patients Ask About HCQ in India

1. Cost: At ₹1,000–2,700/month, HCQ cancer protocols are trivially cheap compared to standard oncology drugs
2. Availability: No supply constraints; India is the global manufacturing hub
3. Off-label access: Indian physicians have more latitude for off-label prescribing than US/UK counterparts
4. Combination potential: Access to affordable combination partners (generic chemotherapy, targeted therapy)

Important Caveats

• No Indian cancer center has published HCQ-specific oncology protocols
• Clinical trial enrollment (US, Europe) remains the recommended access route
• Self-medication at oncology doses carries serious retinal and cardiac risk
• The “₹5/day cancer cure” narrative oversimplifies contradictory evidence
• Patients should seek oncologists familiar with the specific trial evidence

The Bottom Line

Hydroxychloroquine in oncology is a story of extraordinary promise undermined by inconsistent execution. An 85% response rate in melanoma. 100% recurrence-free survival in breast cancer. But also 0% response rates in lung cancer, worsened survival in pancreatic cancer, and a fundamental inability to reliably inhibit autophagy at tolerable doses.

The drug costs ₹5/day in India. That’s not the barrier. The barrier is identifying which patients, in which cancers, with which combinations, will actually benefit — and ensuring they don’t develop irreversible retinal damage in the process.

Until BAMM2 and LIMIT trial results emerge (expected 2027–2028), HCQ remains an investigational oncology agent with flashes of brilliance surrounded by sobering failures. India’s role is as manufacturer and potential access point — but the science must lead the prescription.